ACP
AVBP icon

Acuta Capital Partners’s ArriVent BioPharma AVBP Stock Holding History

Acuta Capital Partners’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.6M Buy
+218,694
New +$6.45M 5.29% 5

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acuta Capital Partners's AVBP Position: Q2 2026 in Review

Acuta Capital Partners opened a new position in ArriVent BioPharma (AVBP) in Q2 2026: 218,694 shares worth $7.6M. The stake represents 5.29% of the portfolio and ranks #5 among its holdings.

157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Acuta Capital Partners held 218,694 shares of ArriVent BioPharma worth $7.6M as of Q2 2026.
  • ArriVent BioPharma was a new Acuta Capital Partners position in Q2 2026.
  • ArriVent BioPharma made up 5.29% of Acuta Capital Partners's portfolio in Q2 2026, its #5 holding.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.